1 Department of Virology, Swedish Institute for Infectious Disease Control and Microbiology and Tumorbiology Center, Karolinska Institutet, SE-171 82 Solna, Sweden
2 Unit of Virology, Division of Medical Microbiology, Department of Laboratory Medicine, Lund University, SE-223 62 Lund, Sweden
3 Department of Infectious Diseases/Solna, Karolinska University Hospital, Karolinska Institutet, SE-171 76 Stockholm, Sweden
4 Department of Infectious Diseases/Huddinge, Karolinska University Hospital, Karolinska Institutet, SE-141 86 Stockholm, Sweden
Correspondence
Jan Albert
Jan.Albert{at}smi.ki.se
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
An amino acid sequence alignment of the V1, V2 and V3 domains of the HIV-2 envelope protein is available as supplementary material in JGV Online.
The GenBank/EMBL/DDBJ accession numbers for the sequences determined in this study are DQ213026DQ213040.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The reasons for the differences between HIV-1 and HIV-2 infection remain unclear, but several factors have been suggested to contribute. Better immune control of HIV-2 than HIV-1 is an obvious possibility. Indeed, cross-sectional studies have indicated that autologous neutralizing-antibody responses are more common in HIV-2 infection than in HIV-1 infection (Björling et al., 1993; Fenyö & Putkonen, 1996
; Tamalet et al., 1995
). Differences have also been reported in cytotoxic T-lymphocyte (CTL) responses, levels of apoptosis, production of
-chemokines and capability of CD4+ and CD8+ lymphocytes to produce interleukins 2 and 4, as well as gamma interferon (Andersson, 2001
; Reeves & Doms, 2002
). However, a recent study reported no differences in cellular immune responses between HIV-1- and HIV-2-infected Gambian patients (Jaye et al., 2004
).
Prior to this study, there have been no studies on the evolution of autologous neutralizing-antibody responses in HIV-2 infection. However, for HIV-1, it has been shown that escape from neutralization by antibodies is frequent and rapid in early infection (Albert et al., 1990; Richman et al., 2003
; von Gegerfelt et al., 1991
; Wei et al., 2003
) and that autologous neutralizing-antibody responses are frequently low or absent later in infection (Ariyoshi et al., 1992
; Fenyö & Putkonen, 1996
; Homsy et al., 1990
; Scarlatti et al., 1993
; von Gegerfelt et al., 1991
). Similarly, there is very limited information on heterologous neutralization of primary HIV-2 isolates, whereas it is known that heterologous neutralization of primary HIV-1 isolates is often absent or of low titre, except in some long-term non-progressors (Carotenuto et al., 1998
; Dreyer et al., 1999
; Scarlatti et al., 1993
; Weber et al., 1996
).
For effective infection of target cells, most HIV-1 and HIV-2 isolates require binding to a chemokine coreceptor, in addition to the CD4 receptor. The CCR5 receptor is used by the majority of primary HIV-1 isolates (R5 viruses), but some isolates from patients with more advanced immunodeficiency use CXCR4 instead of (X4 viruses) or in addition to (X4R5 viruses) CCR5 (Åsjö et al., 1986; Björndal et al., 1997
; Tersmette et al., 1988
; Zhang et al., 1996
). The presence of X4 virus, as well as a switch from CCR5 to CXCR4 usage, is associated with accelerated rate of disease progression (Connor et al., 1997
; Koot et al., 1993
). CCR5 and CXCR4 are the major coreceptors for HIV-1, but a minor proportion of primary HIV-1 isolates can also utilize other alternative coreceptors (CCR1, CCR2, CCR3, CXCR6 or BOB) in vitro (Björndal et al., 1997
; Rucker et al., 1997
). In contrast to HIV-1, HIV-2 isolates can frequently use alternative coreceptors in vitro (Blaak et al., 2005
; McKnight et al., 1998
; Mörner et al., 1999b
). However, CCR5 and CXCR4 also appear to be the major coreceptors for HIV-2 (Blaak et al., 2005
; Mörner et al., 2002
). Some primary HIV-2 isolates can infect coreceptor-positive cells in the absence of CD4 (Clapham et al., 1992
; Reeves et al., 1999
) and such isolates are highly sensitive to neutralizing antibodies (Thomas et al., 2003
).
In this study, we provide the first data on evolution of autologous neutralizing-antibody responses and coreceptor usage of viruses isolated sequentially from four HIV-2-infected individuals. Moreover, we examined the env gene sequences of 15 HIV-2 isolates. We propose that the HIV-2 V3 domain has a more open and accessible configuration than that of HIV-1. This may explain the higher sensitivity to neutralizing antibodies and the broader use of alternative coreceptors.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
The study was approved by the medical ethics committee of the Karolinska Institute (nos 96-189 and 99-462).
Virus stocks and coreceptor usage.
Virus stocks were prepared as described previously (Shi et al., 2002). The infectivity of the HIV-2 isolates was determined by triplicate titration on U87.CD4 cells expressing CXCR4 or CCR5 (Shi et al., 2002
). The coreceptor usage of the HIV-2 isolates was determined by using U87.CD4 cells expressing CCR1, CCR2, CCR3, CCR5 or CXCR4 and GHOST(3) cells expressing CCR3, CCR5, CXCR4, CXCR6 or BOB (Karlsson et al., 2003
). Parental U87.CD4 and GHOST(3) cells without coreceptors were also included. The GHOST(3) cells were tested with and without the CXCR4 antagonist AMD3100. Presence of many syncytia and high HIV-2 p27 antigen levels were scored as strong usage of a specific coreceptor. Presence of low HIV-2 p27 levels in the absence of syncytia was scored as weak coreceptor usage. Absence of both syncytia and HIV-2 p27 antigen was scored as no usage of a specific coreceptor. All tests were repeated at least twice. HIV-2 p27 antigen levels were tested by using Murex HIVag mAb (Murex Biotech).
Neutralization assay.
The levels of autologous neutralizing antibodies were determined by using a recently developed assay based on plaque formation in U87.CD4 cells (Shi et al., 2002). Briefly, the virus stocks were diluted to contain a final concentration of 2050 p.f.u. per well. In all neutralization experiments, we used IgG that had been purified from patients' sera to avoid false-positive neutralization due to the presence of antiretroviral drugs. IgG was purified by using protein Gsepharose 4 Fast Flow (Pharmacia Biotech) according to the instructions of the manufacturers and quantified by using an in-house ELISA. The purified IgG was used at a concentration that corresponded to a 1 : 30 dilution of the original serum. VirusIgG mixtures were kept at 37 °C for 1 h and then further diluted in two to three fivefold-dilution steps. Each virusIgG dilution (200 µl) was distributed into triplicate wells (or duplicate wells when the volume of serum was limited) containing the U87.CD4-CXCR4 or U87.CD4-CCR5 cells. Results are presented as means of parallel determinations. Positive virus controls consisted of wells with cells and virus, but no serum; negative virus controls consisted of wells with virus only; cell controls consisted of wells with cells only. The experiment was terminated on day 3 or day 4 by fixation with methanol : acetone (1 : 1). The number of p.f.u. was determined following haematoxylin staining. The neutralizing capacity of the serum was calculated by the formula [1(p.f.u. with serum/p.f.u. without serum) x100] and thus expresses the degree of reduction in p.f.u. in the presence of serum relative to wells without serum. The cut-off for neutralization for this assay has been derived statistically and was determined to be a 30 % reduction in the number of plaques. The assay qualitatively compares well with traditional PBMC-based HIV-neutralization assays and has good reproducibility (Shi et al., 2002
). However, the percentage plaque reduction in our assay does not translate directly into traditional neutralizing titres and therefore we focused on qualitative, rather than quantitative, aspects of the neutralization results.
HIV-2 env gene sequencing.
HIV-2 RNA was extracted from 200 µl virus-infected supernatant from PBMC cultures by using a NucliSense Isolation kit (Organon Teknika) according to the manufacturer's recommendations. A 1588 bp fragment encompassing the entire gp125 coding sequence was amplified by nested RT-PCR. The PCR was carried out in a 50 µl reaction mixture containing 1x PCR buffer (Applied Biosystems), 2·5 mM MgCl2 (Applied Biosystems), 50 µM each dNTP (Amersham Pharmacia), 0·1 µM each primer (Table 2), 1 U AmpliTaq DNA polymerase (Applied Biosystems), 5 U reverse transcriptase (M-MuLV; Roche Diagnostics) and 28 U rRNasin RNase inhibitor (Promega). The RT-PCR profile consisted of reverse transcription at 37 °C for 60 min, denaturation at 92 °C for 5 min, 30 amplification cycles of 20 s at 92 °C, 20 s at 55 °C and 1 min at 72 °C, and final elongation at 72 °C for 5 min. A portion of the PCR product (2·5 µl) was used as the template for nested PCR; the mixture for the nested PCR contained the same reagents as the mixture for the first PCR, except for reverse transcriptase and RNasin. The amplification profile of the nested PCR was identical to that the first PCR, except that the initial reverse-transcription step at 37 °C was omitted.
|
The Sequencher software (Gene Codes Corporation) was used to edit the sequences and construct sequence contigs. The BioEdit software (Hall, 1999) was used to construct alignments of HIV-2 env gene sequences. Phylogenetic trees were constructed from a gap-stripped alignment by using the MEGA v2.1 software (Kumar et al., 2001
) with the Kimura nucleotide-substitution model (Kimura, 1980
) and the neighbour-joining method (Saitou & Nei, 1987
). Reference sequences for these phylogenetic trees were obtained from the Los Alamos National Laboratory HIV sequence database (www.hiv.lanl.gov).
Potential N-linked glycosylation sites were identified by using the N-GLYCOSITE software available at the website of the Los Alamos National Laboratory HIV sequence database. The isolates were not clonal in sequence and some of the intrasample sequence polymorphisms involved potential N-linked glycosylation sites. In our calculations of the number of potential N-linked glycosylation sites, we have not distinguished between glycosylation sites that were present in part or all of the virus population. Changes in glycosylation sites over time were calculated by comparing each sequence to the closest previous sequence from the same patient. Glycosylation sites were considered to have moved (counted as one event) if a glycosylation site was lost and gained within three amino acid positions, whereas losses and gains of glycosylation sites at longer distances were counted as two events.
Statistical analyses.
Statistical analyses were complicated by the fact that observations on our 15 HIV-2 isolates could not be considered to be independent because the isolates were obtained sequentially from four individuals. For this reason, we deliberately avoided extensive statistical testing. When statistical analyses were performed, we used the Statistica v6.1 software (Statsoft Inc.).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
HIV-2 coreceptor usage associated with the degree of immunodeficiency
The coreceptor usage of the HIV-2 isolates was tested on U87.CD4 and GHOST(3) cells expressing different chemokine coreceptors (Table 1). In accordance with earlier studies of HIV-2 coreceptor usage, most isolates could use several alternative coreceptors (CCR1, CCR2, CCR3, CXCR6 and BOB) in addition to one or both of the two major coreceptors (CCR5 and CXCR4). However, none of the isolates replicated in the parental U87.CD4 or GHOST(3) cells that lacked coreceptors.
In two patients (patients 1 and 4), we observed an acquisition of the ability to use the CXCR4 coreceptor. Interestingly, the ability of the isolates to infect through CXCR4 appeared to be associated with the immunological status of the patients. Thus, all isolates, except one, that could infect through the CXCR4 receptor were obtained at time points when the CD4 counts of the respective patients were below 200 cells µl1. Conversely, R5 isolates were obtained at time points when the patients had higher CD4 counts.
Autologous-neutralization escape is rare in HIV-2 infection
The evolution of autologous neutralization was tested in a chequerboard fashion with purified IgG from sequentially collected sera by using a recently described method based on plaque formation in U87.CD4 cells (Shi et al., 2002). Significant autologous neutralization (>30 % plaque reduction) was observed for the majority (39 of 54) of the tested serumvirus combinations (Fig. 1
). Importantly, we observed no consistent pattern of neutralization escape in our four study subjects. Thus, many sera could neutralize autologous viruses that had been isolated many years later.
|
Broad neutralization of heterologous primary HIV-2 isolates
To investigate whether HIV-2 sera also can neutralize heterologous primary HIV-2 isolates, we tested the ability of IgG purified from 18 HIV-2 sera from 15 Swedish patients to neutralize six heterologous HIV-2 isolates (Table 3). The isolates consisted of one isolate from each of our four study subjects, the reference HIV-2 subtype A isolate 6669 (Albert et al., 1987
, 1996
) and the HIV-2 subtype B isolate 1653 (Albert et al., 1996
). The main observation was that significant neutralization was observed for the majority of the virusIgG combinations, i.e. 84 of 97 tests (87 %). Furthermore, there was no obvious association between the neutralization results and the CD4 count of the patient from whom the serum was drawn. Thus, serum P4-2001, which was obtained when the patient had a CD4 count of 30 cells µl1, could neutralize all five heterologous HIV-2 primary isolates. Similarly, there was no obvious association between the neutralization results and the coreceptor usage of the virus. A few interesting details from the heterologous-neutralization experiments should be noted. The X4 isolate P4-V2000 was comparably resistant to heterologous neutralization, as significant neutralization was observed with only six of 15 sera, even though this isolate was neutralized by all four autologous sera (Fig. 1
). Furthermore, virus P8-V1998, which was neutralized poorly by autologous sera (Fig. 1
), was neutralized efficiently by all heterologous HIV-2 sera. This indicates that the poor autologous neutralization that we observed in patient 8 was due to the immunological status of this patient, rather than the characteristics of the virus. Finally, isolate 1653, which is of HIV-2 subtype B, was neutralized by 13 of 15 sera, even though they, when known, were obtained from patients infected with subtype A virus (Brandin et al., 2003
). Thus, the ability of HIV-2 sera to cross-neutralize heterologous HIV-2 isolates appears to extend to other HIV-2 subtypes.
|
|
|
V3 sequence is associated with coreceptor usage
We found an association between the overall charge of the HIV-2 V3 loop and coreceptor usage (Fig. 2). All isolates that could use CCR5 efficiently had V3 loops with a net charge of +5 or +6, whereas all isolates that were unable to use this receptor efficiently had a charge of +7. A reverse dependence was observed between V3 charge and CXCR4 usage. Thus, all isolates that could use CXCR4 efficiently had V3 loop charges of +7, except for the dual-tropic isolate P4-2001, which had a charge of +6. Isolates that were unable to use CXCR4 efficiently had V3 loop charges of +5 or +6.
We also found that all six isolates that lacked the ability to infect efficiently through the CCR5 receptor displayed positively charged amino acids (arginine or lysine) at position 323 in the V3 loop (corresponding to position 19 in Fig. 2), whereas all nine isolates that could use CCR5 displayed neutral amino acids (valine or isoleucine) at this position. Furthermore, positively charged amino acids at position 323 characterized six of seven isolates that could infect efficiently through the CXCR4 receptor, but none of the CXCR4-negative isolates.
Changes in overall glycosylation pattern associated with disease progression
Recent data indicate that neutralization escape in HIV-1 infection may involve changes in glycosylation pattern (Wei et al., 2003). N-linked glycosylation may also influence coreceptor usage in HIV-1 (Nabatov et al., 2004
; Ogert et al., 2001
; Pollakis et al., 2001
; Polzer et al., 2002
). For this reason, we examined changes in potential N-linked glycosylation sites in our HIV-2 isolates in relation to neutralization, coreceptor usage and clinical progression.
The number of potential N-linked glycosylation sites varied between 24 and 29 (Table 4) and there was a tendency for the glycosylation sites to increase in number over time. Furthermore, viruses with longer V1/V2 regions tended to have a higher number of potential N-linked glycosylation sites.
We also examined changes in the positioning and presence of glycosylation sites over time (Table 4; Supplementary Figure). There were substantial differences in the number of changes of N-linked glycosylation sites between isolates and patients. The highest number of changes was observed in the 1991 isolate of patient 1 (compared with the preceding 1986 isolate). The lowest number, i.e. no change at all, was observed for the March 2001 sample and the 2002 sample from patient 8.
The number of changes in N-linked glycosylation sites was linked to the clinical and immunological status of the patients. Thus, the highest number of changes was observed in patients 1 and 2, who had moderate immunodeficiency, an intermediate number was observed in patient 4 and the lowest number was observed in patient 8, who had the most advanced immunodeficiency.
Glycosylation of the V3 region differed between HIV-1 and HIV-2
The glycosylation pattern of our HIV-2 isolates was also inspected for possible correlation with coreceptor usage and neutralization. One glycosylation site just downstream of the HIV-2 V3 loop, i.e. at position 40 in Fig. 2, appeared to be associated with the coreceptor usage of our HIV-2 isolates. However, this association was probably coincidental, because it does not hold true for previously published HIV-2 isolates with known env sequence and coreceptor usage (data not shown). Similarly, the neutralization sensitivity of our isolates did not correlate with the overall number of N-linked glycosylation sites or the absence or presence of specific glycosylation sites. The most important finding was that the HIV-2 isolates had fewer potential glycosylation sites in the V3 domain than have been reported for HIV-1, i.e. two to three for HIV-2 versus four to five for HIV-1 (Figs 2 and 3
). This is interesting because the glycosylation pattern in the HIV-1 V3 domain has been reported to influence the neutralization sensitivity and coreceptor usage of HIV-1 isolates (McCaffrey et al., 2004
; Nabatov et al., 2004
; Polzer et al., 2002
; Schønning et al., 1996
).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our study is the first investigation of the evolution of autologous neutralizing-antibody responses in HIV-2 infection. The main finding is that neutralization escape appears rare in HIV-2 infection, even though some primary HIV-2 isolates are more difficult to neutralize than others. This is in contrast to HIV-1 infection, where neutralization escape is common and patients' sera are rarely capable of neutralizing contemporaneous autologous virus isolates (Albert et al., 1990; Ariyoshi et al., 1992
; Fenyö & Putkonen, 1996
; Homsy et al., 1990
; Richman et al., 2003
; Scarlatti et al., 1993
; von Gegerfelt et al., 1991
; Wahlberg et al., 1991
; Wei et al., 2003
). However, it should be pointed out that our patients were not followed from the time of infection, thus it is possible that neutralization escape early after infection may have been missed. Furthermore, sera from HIV-2-infected patients with varying severity of disease were capable of cross-neutralizing a panel of six heterologous primary HIV-2 isolates. This also differs from the findings in HIV-1 infection (Carotenuto et al., 1998
; Dreyer et al., 1999
; Scarlatti et al., 1993
; Weber et al., 1996
). Dreyer et al. (1999)
found that antiretroviral drugs contributed to neutralization in some sera. Such an influence from antiretroviral therapy can be ruled out in our study, because we used IgG that had been purified from the sera of the HIV-2-infected individuals. In our study, all HIV-2 sera neutralized the majority of the six heterologous primary HIV-2 isolates, including the HIV-2 subtype B isolate 1653. Some HIV-2 sera were even able to cross-neutralize HIV-1 (Weiss et al., 1988
). Taken together, our and previous studies show that there are fundamental differences between HIV-1 and HIV-2 in the induction of and sensitivity to neutralizing antibodies. Natural HIV-2 infection, but not HIV-1 infection, appears to induce broadly neutralizing antibody responses. Furthermore, HIV-2 appears intrinsically less able than HIV-1 to evade these neutralizing-antibody responses. Whether these important differences are a cause or a consequence of the lower virulence of HIV-2 remains to be elucidated.
In this study, we have shown for the first time that HIV-2 can evolve from CCR5 use to CXCR4 use in infected patients. The acquisition of CXCR4 usage was linked closely to the immunological status of the patients. Thus, all CXCR4-using isolates, except one, were isolated when the CD4 counts of the patients were lower than 200 cells µl1. This is in agreement with a large number of studies on HIV-1, which have shown that CXCR4-using viruses are rare in early HIV-1 infection, but can be isolated from approximately 50 % of patients with AIDS (Åsjö et al., 1986; Björndal et al., 1997
; Tersmette et al., 1988
; Zhang et al., 1996
). In HIV-1 infection, the emergence of CXCR4-using virus variants is associated directly with an accelerated rate of decline of CD4 counts (Connor et al., 1997
; Koot et al., 1993
). It is possible that the same is true for HIV-2 infection, but larger studies are needed to explore this.
Our study shows that many primary HIV-2 isolates can use one or several alternative coreceptors (CCR1, CCR2, CCR3, CXCR6 or BOB) in addition to CCR5 and/or CXCR4. This confirms the findings of earlier studies (Blaak et al., 2005; McKnight et al., 1998
; Mörner et al., 1999b
). We have chosen to refer to these receptors as alternative coreceptors, because it is unclear whether they are utilized in vivo (Blaak et al., 2005
; Mörner et al., 2002
). Some HIV-2 isolates displayed an R5X4 phenotype, but we did not investigate whether individual viral clones were dually tropic or whether the isolates contained a mixture of R5 and X4 clones.
We found that HIV-2, like HIV-1 (Fouchier et al., 1992; Nabatov et al., 2004
; Pollakis et al., 2001
), displays an association between the charge of the V3 loop and coreceptor use. Thus, all of our HIV-2 isolates with low V3 charge (+5 or +6) used CCR5, whereas isolates with higher V3 charge (+7) preferred CXCR4. These results are in agreement with our earlier finding that rapid/high HIV-2 isolates had a higher V3 charge than slow/low HIV-2 isolates (Albert et al., 1996
), as well as with the results of Isaka et al. (1999)
, who also showed that the HIV-2 V3 domain contains determinants for coreceptor use, as exchange of the C-terminal half of the V3 loop between the laboratory HIV-2 strains ROD and GH-1 altered the coreceptor use reciprocally. At present, it is unclear whether the exact positioning of positively charged amino acids in the HIV-2 V3 loop also influences the coreceptor usage. However, we saw a preference for positively charged amino acids (lysine or arginine) at position 19 in the V3 loop in X4 HIV-2 isolates, similar to the preference for positively charged amino acids at positions 11 and 25 in X4 HIV-1 isolates (De Jong et al., 1992
; Fouchier et al., 1992
).
We believe that the high sensitivity to neutralizing antibodies, the inability to escape neutralization and broad coreceptor use of HIV-2 may be due to differences in the structure of the V3 domain between HIV-1 and HIV-2. As described above, the V3 domain is a determinant for coreceptor use of both HIV-1 and HIV-2. Furthermore, the V3 domain of both HIV-1 and HIV-2 contains neutralizing epitopes (Goudsmit et al., 1988; Javaherian et al., 1989
; McKnight et al., 1996
; Mörner et al., 1999a
; Rusche et al., 1988
). We observed that HIV-2 isolates only have two or, in a few cases, three potential N-linked glycosylation sites in and around the V3 loop, whereas HIV-1 isolates have four or five (Fig. 3
). In HIV-1, these glycosylation sites appear to be utilized (Ogert et al., 2001
; Polzer et al., 2002
), but it is unknown whether the same is true for HIV-2. We propose that these differences in glycan packing confer a more open and accessible V3 domain on HIV-2 compared with HIV-1. The more open envelope configuration may explain the broader coreceptor usage and greater sensitivity to neutralizing antibodies of HIV-2. In support of this hypothesis, it has been shown for HIV-1 that deglycosylation of the V3 loop may lead to a broadening of the coreceptor repertoire to include CCR3 (Pollakis et al., 2001
). Furthermore, several studies have shown that removal of glycans in and around the HIV-1 V3 loop may increase the sensitivity to neutralizing antibodies (Benjouad et al., 1992
; McCaffrey et al., 2004
; Nabatov et al., 2004
; Polzer et al., 2002
; Schønning et al., 1996
). An additional interesting observation is that HIV-2 isolates that can infect coreceptor-positive cells in the absence of CD4 are highly sensitive to neutralizing antibodies (Clapham et al., 1992
; Thomas et al., 2003
).
We studied four HIV-2-infected patients who had moderate to advanced HIV-2 disease. Clearly, it would have been interesting to also study patients with fully asymptomatic HIV-2 infection, but such patients from our cohort could not be included in this study because attempts to isolate virus were generally unsuccessful. This difficulty in isolating virus from asymptomatic HIV-2 carriers is in agreement with results from other researchers (Simon et al., 1993). However, it has been reported that HIV-2 may be isolated more frequently if CD8 cells are depleted from the cultures. Recent studies on neutralization of HIV-1 have utilized plasma-derived SU proteins in recombinant virus-neutralization assays (Richman et al., 2003
; Wei et al., 2003
). We are developing such an assay for HIV-2, but we will still be unable to study asymptomatic HIV-2 carriers because they typically have undetectable plasma HIV-2 levels (Andersson et al., 2000
; Berry et al., 1998
; Brandin et al., 2003
; Popper et al., 1999
).
We noted that the immunological status of the patients was associated with the length of the V1/V2 domain and changes in glycosylation pattern. Thus, the virus carried by patients 1 and 2, who had relatively high CD4 counts, displayed a marked elongation of the V1/V2 domain and a high number of glycosylation changes. In contrast, patient 8, who had advanced immunodeficiency, displayed a stable V1/V2 length and few changes in glycosylation pattern. Interestingly, the elongation of the V1/V2 domain was primarily due to insertions of threonine residues and thereby increased the number of potential O-linked glycosylation sites. Similar changes in the V1/V2 domain correlate with neutralizing-antibody responses and neutralization escape in experimental simian immunodeficiency virus (SIVsm and SIVmne) infection (Chackerian et al., 1997; Rybarczyk et al., 2004
). Both of these viruses are members of the HIV-2/SIVsm family and thus are related closely to HIV-2. It is known that the V1/V2 domain of HIV-2 also contains neutralizing epitopes (McKnight et al., 1996
). Many studies show that neutralization escape in HIV-1 and SIV frequently involves changes in glycosylation pattern (Benjouad et al., 1992
; Chackerian et al., 1997
; Derdeyn et al., 2004
; McCaffrey et al., 2004
; Nabatov et al., 2004
; Polzer et al., 2002
; Schønning et al., 1996
; Wei et al., 2003
). Thus, it is possible that the changes that we observed in the V1/V2 region of HIV-2 could be immunologically driven, but this possibility appears to be contradicted by the fact that we did not observe neutralization escape. However, it is possible that the putative neutralizing epitopes in the HIV-2 V1/V2 region resemble subdominant CTL epitopes (Goulder et al., 2001
), so that mutations in these epitopes do not lead to complete neutralization escape.
The hypothesis that we present concerning the mechanisms for evolution and interdependence between HIV-2 neutralization escape, coreceptor usage and glycosylation pattern is testable. Thus, we aim to produce infectious clones of HIV-2 with different biological characteristics. Through mutagenesis and construction of HIV-2 chimeras, we will try to verify formally whether the HIV-2 V3 domain has a more open configuration than that of HIV-1, and also to identify the molecular determinants for the biological properties listed above.
![]() |
ACKNOWLEDGEMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Albert, J., Abrahamsson, B., Nagy, K., Aurelius, E., Gaines, H., Nyström, G. & Fenyö, E. M. (1990). Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107112.[Medline]
Albert, J., Stalhandske, P., Marquina, S., Karis, J., Fouchier, R. A., Norrby, E. & Chiodi, F. (1996). Biological phenotype of HIV type 2 isolates correlates with V3 genotype. AIDS Res Hum Retroviruses 12, 821828.[Medline]
Andersson, S. (2001). HIV-2 and the immune response. AIDS Rev 3, 1123.
Andersson, S., Norrgren, H., da Silva, Z., Biague, A., Bamba, S., Kwok, S., Christopherson, C., Biberfeld, G. & Albert, J. (2000). Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 160, 32863293.
Andreasson, P. A., Dias, F., Naucler, A., Andersson, S. & Biberfeld, G. (1993). A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 7, 989993.[Medline]
Ariyoshi, K., Harwood, E., Chiengsong-Popov, R. & Weber, J. (1992). Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet 340, 12571258.[CrossRef][Medline]
Åsjö, B., Morfeldt-Månsson, L., Albert, J., Biberfeld, G., Karlsson, A., Lidman, K. & Fenyö, E. M. (1986). Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet ii, 660662.
Benjouad, A., Gluckman, J.-C., Rochat, H., Montagnier, L. & Bahraoui, E. (1992). Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J Virol 66, 24732483.[Abstract]
Berry, N., Ariyoshi, K., Jaffar, S., Sabally, S., Corrah, T., Tedder, R. & Whittle, H. (1998). Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1, 457468.[Medline]
Björling, E., Scarlatti, G., von Gegerfelt, A., Albert, J., Biberfeld, G., Chiodi, F., Norrby, E. & Fenyö, E. M. (1993). Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193, 528530.[CrossRef][Medline]
Björndal, A., Deng, H., Jansson, M. & 7 other authors (1997). Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71, 74787487.[Abstract]
Blaak, H., Boers, P. H. M., Gruters, R. A., Schuitemaker, H., van der Ende, M. E. & Osterhaus, A. D. M. E. (2005). CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol 79, 16861700.
Brandin, E., Lindborg, L., Gyllensten, K., Brostrom, C., Hagberg, L., Gisslen, M., Tuvesson, B., Blaxhult, A. & Albert, J. (2003). pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 19, 543550.[CrossRef][Medline]
Carotenuto, P., Looij, D., Keldermans, L., de Wolf, F. & Goudsmit, J. (1998). Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12, 15911600.[CrossRef][Medline]
CDC (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41, 119.[Medline]
Chackerian, B., Rudensey, L. M. & Overbaugh, J. (1997). Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 71, 77197727.[Abstract]
Clapham, P. R., McKnight, Á. & Weiss, R. A. (1992). Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol 66, 35313537.[Abstract]
Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S. & Landau, N. R. (1997). Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185, 621628.
De Jong, J.-J., De Ronde, A., Keulen, W., Tersmette, M. & Goudsmit, J. (1992). Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66, 67776780.[Abstract]
Derdeyn, C. A., Decker, J. M., Bibollet-Ruche, F. & 11 other authors (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 20192022.
Dreyer, K., Kallas, E. G., Planelles, V., Montefiori, D., McDermott, M. P., Hasan, M. S. & Evans, T. G. (1999). Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 15, 15631571.[CrossRef][Medline]
Fenyö, E. M. & Putkonen, P. (1996). Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. Immunol Lett 51, 9599.[CrossRef][Medline]
Fouchier, R. A. M., Groenink, M., Kootstra, N. A., Tersmette, M., Huisman, H. G., Miedema, F. & Schuitemaker, H. (1992). Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66, 31833187.[Abstract]
Goudsmit, J., Debouck, C., Meloen, R. H., Smit, L., Bakker, M., Asher, D. M., Wolff, A. V., Gibbs, C. J., Jr & Gajdusek, D. C. (1988). Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A 85, 44784482.
Goulder, P. J. R., Brander, C., Tang, Y. & 16 other authors (2001). Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334338.[CrossRef][Medline]
Hall, T. A. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41, 9598.
Homsy, J., Meyer, M. & Levy, J. A. (1990). Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 64, 14371440.[Medline]
Isaka, Y., Sato, A., Miki, S. & 8 other authors (1999). Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology 264, 237243.[CrossRef][Medline]
Javaherian, K., Langlois, A. J., McDanal, C. & 8 other authors (1989). Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A 86, 67686772.
Jaye, A., Sarge-Njie, R., van der Loeff, M. S., Todd, J., Alabi, A., Sabally, S., Corrah, T. & Whittle, H. (2004). No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients. J Infect Dis 189, 498505.[CrossRef][Medline]
Kanki, P. J., Travers, K. U., Mboup, S. & 9 other authors (1994). Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343, 943946.[CrossRef][Medline]
Karlsson, I., Antonsson, L., Shi, Y., Karlsson, A., Albert, J., Leitner, T., Olde, B., Owman, C. & Fenyö, E. M. (2003). HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 17, 25612569.[CrossRef][Medline]
Kimura, M. (1980). A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16, 111120.[Medline]
Koot, M., Keet, I. P. M., Vos, A. H. V., de Goede, R. E. Y., Roos, M. T. L., Coutinho, R. A., Miedema, F., Schellekens, P. T. A. & Tersmette, M. (1993). Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118, 681688.
Kumar, S., Tamura, K., Jakobsen, I. B. & Nei, M. (2001). MEGA2: molecular evolutionary genetic analysis software. Bioinformatics 17, 12441245.
Marlink, R., Kanki, P., Thior, I. & 13 other authors (1994). Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265, 15871590.[Medline]
McCaffrey, R. A., Saunders, C., Hensel, M. & Stamatatos, L. (2004). N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78, 32793295.
McKnight, Á., Shotton, C., Cordell, J., Jones, I., Simmons, G. & Clapham, P. R. (1996). Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol 70, 45984606.[Abstract]
McKnight, Á., Dittmar, M. T., Moniz-Periera, J. & 8 other authors (1998). A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 72, 40654071.
Mörner, A., Achour, A., Norin, M., Thorstensson, R. & Björling, E. (1999a). Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2. Virus Res 59, 4960.[CrossRef][Medline]
Mörner, A., Björndal, Å., Albert, J., KewalRamani, V. N., Littman, D. R., Inoue, R., Thorstensson, R., Fenyö, E. M. & Björling, E. (1999b). Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 73, 23432349.
Mörner, A., Björndal, Å., Leandersson, A.-C., Albert, J., Björling, E. & Jansson, M. (2002). CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. AIDS Res Hum Retroviruses 18, 193200.[CrossRef][Medline]
Nabatov, A. A., Pollakis, G., Linnemann, T., Kliphius, A., Chalaby, M. I. M. & Paxton, W. A. (2004). Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 78, 524530.
Ogert, R. A., Lee, M. K., Ross, W., Buckler-White, A., Martin, M. A. & Cho, M. W. (2001). N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J Virol 75, 59986006.
Pepin, J., Morgan, G., Dunn, D., Gevao, S., Mendy, M., Gaye, I., Scollen, N., Tedder, R. & Whittle, H. (1991). HIV-2-induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS 5, 11651172.[Medline]
Pollakis, G., Kang, S., Kliphuis, A., Chalaby, M. I. M., Goudsmit, J. & Paxton, W. A. (2001). N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 276, 1343313441.
Polzer, S., Dittmar, M. T., Schmitz, H. & Schreiber, M. (2002). The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304, 7080.[CrossRef][Medline]
Popper, S. J., Sarr, A. D., Travers, K. U., Guèye-Ndiaye, A., Mboup, S., Essex, M. E. & Kanki, P. J. (1999). Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 180, 11161121.[CrossRef][Medline]
Reeves, J. D. & Doms, R. W. (2002). Human immunodeficiency virus type 2. J Gen Virol 83, 12531265.
Reeves, J. D., Hibbitts, S., Simmons, G., McKnight, Á., Azevedo-Pereira, J. M., Moniz-Pereira, J. & Clapham, P. R. (1999). Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 73, 77957804.
Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100, 41444149.
Rucker, J., Edinger, A. L., Sharron, M. & 9 other authors (1997). Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 71, 89999007.[Abstract]
Rusche, J. R., Javaherian, K., McDanal, C. & 10 other authors (1988). Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A 85, 31983202.
Rybarczyk, B. J., Montefiori, D., Johnson, P. R., West, A., Johnston, R. E. & Swanstrom, R. (2004). Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol 78, 35613571.
Saitou, N. & Nei, M. (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4, 406425.[Abstract]
Scarlatti, G., Albert, J., Rossi, P., Hodara, V., Biraghi, P., Muggiasca, L. & Fenyö, E. M. (1993). Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 168, 207210.[Medline]
Schønning, K., Jansson, B., Olofsson, S., Nielsen, J. O. & Hansen, J.-E. S. (1996). Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 218, 134140.[CrossRef][Medline]
Shi, Y., Albert, J., Francis, G., Holmes, H. & Fenyö, E. M. (2002). A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res Hum Retroviruses 18, 957967.[CrossRef][Medline]
Simon, F., Matheron, S., Tamalet, C. & 9 other authors (1993). Cellular and plasma viral load in patients infected with HIV-2. AIDS 7, 14111417.[Medline]
Tamalet, C., Simon, F., Dhiver, C., Matheron, S., de Micco, P., Gastao, J. A. & Brun-Vezinet, F. (1995). Autologous neutralizing antibodies and viral load in HIV-2-infected individuals. AIDS 9, 9091.[Medline]
Tersmette, M., de Goede, R. E. Y., Al, B. J. M., Winkel, I. N., Gruters, R. A., Cuypers, H. T., Huisman, H. G. & Miedema, F. (1988). Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 62, 20262032.[Medline]
Thomas, E. R., Shotton, C., Weiss, R. A., Clapham, P. R. & McKnight, Á. (2003). CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 17, 291300.[CrossRef][Medline]
von Gegerfelt, A., Albert, J., Morfeldt-Månson, L., Broliden, K. & Fenyö, E. M. (1991). Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 185, 162168.[CrossRef][Medline]
Wahlberg, J., Albert, J., Lundeberg, J., von Gegerfelt, A., Broliden, K., Utter, G., Fenyö, E. M. & Uhlen, M. (1991). Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. AIDS Res Hum Retroviruses 7, 983990.[Medline]
Weber, J., Fenyö, E.-M., Beddows, S., Kaleebu, P. & Björndal, A. (1996). Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO network for HIV isolation and characterization. J Virol 70, 78277832.[Abstract]
Wei, X., Decker, J. M., Wang, S. & 12 other authors (2003). Antibody neutralization and escape by HIV-1. Nature 422, 307312.[CrossRef][Medline]
Weiss, R. A., Clapham, P. R., Weber, J. N., Whitby, D., Tedder, R. S., O'Connor, T., Chamaret, S. & Montagnier, L. (1988). HIV-2 antisera cross-neutralize HIV-1. AIDS 2, 95100.[Medline]
Zhang, L., Huang, Y., He, T., Cao, Y. & Ho, D. D. (1996). HIV-1 subtype and second-receptor use. Nature 383, 768.[CrossRef][Medline]
Received 13 June 2005;
accepted 12 August 2005.
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
J MED MICROBIOL | ALL SGM JOURNALS |